

MolMed S.p.A. Company Overview

Leading the way in Cell & Gene therapy
April, 2018



An established dual business model leveraging common technological assets

COMMON ASSETS

- **20+ year experience** in Cell & Gene Therapy Development and Manufacturing
- 140+ highly qualified scientist and operators plus ~40 support staff
- □ 12 proprietary patent families including **256 granted patents** and 43 pending applications
- **2 GMP manufacturing facilities** of almost 5.000SQM, manufacturing of the **only 2** *ex-vivo* gene therapy products **approved in EU**
- Strategical and commercial partnership with primary big players of EU and US bio-pharma industry

Proprietary Pipeline

Research, development, manufacturing and clinical validation of proprietary products

GMP Solutions (CDMO *)

Development and manufacturing for 3rd parties

^{*} Contract Development and Manufacturing Organization




MolMed Cell & Gene anti-tumor therapies proprietary pipeline

Product/ Therapy	Indication	Disc.	Precl	PhI/II	PhIII	Market	
Zalmoxis [®]	Haplo identical Transplant in Hematological Malignancies	_					 Aug 16: EMA CMA EMA Conditional Marketing Authorization Apr-Jul 17: Commercialization & Supply Agreements Europe, Asia, Israel Dec 18: AIFA Reimbursement price €149,000 / infusion Jan 18: P&R* Reimbursement price €163,900 / infusion Feb 18: Dompé option exercise for Switzerland, Turkey, Australia Market Access Activities ONGOING
CAR CD44v6 Liquid tumor	Liquid tumors (leukemia, myeloma)						 Market Access Activities ONGOING High therapeutic potential also in several solid tumors Specifically infiltrating the tumor
CAR CD44v6 Solid tumor	Solid tumors (pancreas, breast, head and neck)						 High safety profile (low skin toxicity) MoMed is Eure CART project coordinator and Phase I/II trial sponsor



GMP Development and Manufacturing service agreements

Recognized GMP capability
with the 1st facility in Europe
to obtain the GMP
manufacturing authorization
for the market





Key Financials: financial results improved significantly in the last three years

- Total FY17 Revenues of 24€ M, with Revenues from sales equal to Euro 23€ M, increased by 18.0% compared to 2016
- Operating and Net Results considerably improved by 40% and 38.8% respectively, compared to 2016
- ☐ Human resources increased year by year, from 152 employees at the end of 2016 to 186 as of December 31st, 2017

			Δ		FY 2015	Δ FY16 vs FY15	
€/000	FY17	FY17	vs FY16	FY 2016			
		€	%			€	%
Operating Revenues	23,987	1,162	5.1%	22,825	16,764	6,061	36,2%
Revenues	23,000	3,516	18.0%	19,484	13,576	5,908	43,5%
Other operating income	987	(2,354)	(70.5%)	3,341	3,188	153	4,8%
Operating costs	32,135	(4,276)	(11.7%)	36,411	37,302	(891)	(2,4%)
Operating Results	(8,148)	5,438	40.0%	(13,586)	(20,538)	6,952	33.8%
Net Result for the period	(8,497)	5,379	38.8%	(13,876)	(20,784)	6,908	33.2%
Net Financial Position ^(*)	18,111			19,702	29,938		
Work Force (#)	186	5		181	152	9	

